Sensitive detection of minimal residual disease in patients treated for early-stage breast cancer

PURPOSE: Existing cell-free DNA (cfDNA) methods lack the sensitivity needed for detecting minimal residual disease (MRD) following therapy. We developed a test for tracking hundreds of patient-specific mutations to detect MRD with a 1000-fold lower error rate than conventional sequencing. EXPERIMENT...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clin Cancer Res
Hauptverfasser: Parsons, Heather A., Rhoades, Justin, Reed, Sarah C., Gydush, Gregory, Ram, Priyanka, Exman, Pedro, Xiong, Kan, Lo, Christopher C., Li, Tianyu, Fleharty, Mark, Kirkner, Greg, Rotem, Denisse, Cohen, Ofir, Yu, Fangyan, Fitarelli-Kiehl, Mariana, Leong, Ka Wai, Hughes, Melissa, Rosenberg, Shoshana M., Collins, Laura C., Miller, Kathy D., Blumenstiel, Brendan, Trippa, Lorenzo, Cibulskis, Carrie, Neuberg, Donna, DeFelice, Matthew, Freeman, Samuel S., Lennon, Niall J., Wagle, Nikhil, Ha, Gavin, Stover, Daniel G., Choudhury, Atish D., Getz, Gad, Winer, Eric P., Meyerson, Matthew, Lin, Nancy U., Krop, Ian E., Love, J. Christopher, Makrigiorgos, G. Mike, Partridge, Ann, Mayer, Erica, Golub, Todd R., Adalsteinsson, Viktor A.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2020
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7654718/
https://ncbi.nlm.nih.gov/pubmed/32170028
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-3005
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge